Study S002237

A Randomized, 24-week, Controlled, Open Label, Parallel Arm, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Type 2 Diabetes Patients, Inadequately Controlled on Basal Insulin With or Without Metformin

ClinicalTrials.gov record

Registration

Registration: NCT03529123
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 247
Start: 2018-06-19
Primary completion: 2019-11-25
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010); DRUG:INSULIN GLARGINE (HOE901); DRUG:Metformin; DRUG:Insulin Glulisine (HMR1964)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1200-1162

Registered primary outcomes

Change in HbA1c [From baseline to Week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.